Arthritis Care & Research最新文献

{"title":"Trajectories of Physical Function in Canadian Children With Juvenile Idiopathic Arthritis.","authors":"Clare Cunningham, Meghan McPherson, Lillian Lim, Roberta A Berard, Matthew Berkowitz, Jean-Philippe Proulx-Gauthier, Brian M Feldman, Nicole Johnson, Dax G Rumsey, Heinrike Schmeling, Lori B Tucker, Thomas Loughin, Kristin M Houghton, Jaime Guzman","doi":"10.1002/acr.80039","DOIUrl":"10.1002/acr.80039","url":null,"abstract":"<p><strong>Objective: </strong>We describe trajectories of physical function in children newly diagnosed with juvenile idiopathic arthritis (JIA) and identify trajectories with persisting functional impairments and associated baseline characteristics.</p><p><strong>Methods: </strong>We included patients enrolled in the Canadian Alliance of Pediatric Rheumatology Investigators (CAPRI) Registry between 2017 and 2024 whose parents provided Kids Disability Screen (KDS) scores from at least two visits (from 0 = no disability to 10 = severe disability). Analyses included descriptive statistics, locally weighted scatterplot smoothing, Kaplan-Meier plots of time to KDS = 0, latent class trajectory analysis (LCTA), and classification trees to predict trajectories with persisting impairments.</p><p><strong>Results: </strong>We included 940 patients providing 7,351 KDS scores starting at a median 6 days after diagnosis up to 7 years. Baseline KDS scores were highest for rheumatoid factor-positive polyarthritis (mean 4.9, SD 3.1) and lowest for psoriatic arthritis (mean 2.4, SD 2.5), and mean scores improved within the first year in all JIA categories. Median time to KDS = 0 was 36 weeks (from 13 weeks for systemic arthritis to 73 weeks for undifferentiated arthritis). LCTA identified five trajectories: one with little measurable impairment (38% of patients), two with impairments resolving in one to two years (24%), and two with persisting mild impairments (38%). A baseline KDS ≥1.5 had a sensitivity of 0.79 and specificity of 0.48 to detect persisting mild impairment trajectories. There were no trajectories with persisting moderate or severe impairments.</p><p><strong>Conclusion: </strong>Most children with JIA in this cohort had mild to moderate functional impairments at diagnosis that resolved in one to two years, but one in three followed trajectories with mild persisting impairments.</p>","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":" ","pages":"1564-1573"},"PeriodicalIF":4.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13613252/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147375877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply.","authors":"Anna Maria Vettori, Michele Iudici","doi":"10.1002/acr.80047","DOIUrl":"10.1002/acr.80047","url":null,"abstract":"","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":" ","pages":"1577-1578"},"PeriodicalIF":4.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147502959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply.","authors":"Anne C Bull Haaversen, Lene K Brekke, Tanaz A Kermani, Øyvind Molberg, Andreas P Diamantopoulos","doi":"10.1002/acr.80061","DOIUrl":"10.1002/acr.80061","url":null,"abstract":"","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":" ","pages":"1575-1576"},"PeriodicalIF":4.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147670048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Building a Framework for Sexual and Reproductive Health Care in the Rheumatology Context: Content and Approaches.","authors":"Mehret Birru Talabi, Sonya Borrero","doi":"10.1002/acr.80049","DOIUrl":"10.1002/acr.80049","url":null,"abstract":"<p><p>People with systemic autoimmune and rheumatic diseases (SARDs) are at higher risk than the general population of experiencing adverse pregnancy and perinatal outcomes such as preeclampsia, intrauterine growth restriction, and maternal and/or fetal death. The immune system undergoes changes during pregnancy that can precipitate adverse health outcomes among people with immunologic dysfunction at baseline-particularly those people who have active inflammatory disease at the time of and/or during pregnancy. However, in this commentary, we challenge the notion that immunologic and disease-centric aspects of pregnancy are the only drivers of adverse pregnancy and perinatal outcomes among people with SARDs. A focus on disease may have limited focus on other factors that could enhance reproductive health outcomes among people with SARDs, for example, the provision of high-quality sexual and reproductive health (SRH) care in the rheumatology context. Identification of such upstream factors can reveal approaches that enhance downstream reproductive outcomes for all women with rheumatic diseases, thereby enhancing person centeredness, holistic care, and SRH equity in rheumatology care. Herein, we also describe emerging approaches to SRH that provide a potential framework for high-quality SRH care in the rheumatology context.</p>","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":" ","pages":"1510-1521"},"PeriodicalIF":4.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13613262/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147608085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rheumatoid Arthritis, Frailty, and Outcomes of Surgical Hospitalizations: A National Population-Based Analysis.","authors":"Ali Yazdanyar, Joshua Baker, Katherine D Wysham, Mohammed Yousufuddin, Farah Acher Kaiksow, Michael M Ward","doi":"10.1002/acr.80171","DOIUrl":"10.1002/acr.80171","url":null,"abstract":"<p><strong>Objective: </strong>Hospitalization, particularly for surgery, represents a period of heightened stress. We evaluated how frailty attenuates the association of rheumatoid arthritis (RA) with negative health outcomes after elective noncardiac surgery.</p><p><strong>Methods: </strong>We conducted a cross-sectional study using the National Inpatient Sample (2018 to 2020), including adults (aged ≥18 years) with elective hospitalizations with noncardiac surgery. Frailty was measured using the Hospital Frailty Risk Score (HFRS). Surgeries were categorized by risk level. Outcomes included discharge health resources need (DHRN), composite adverse clinical events (CACE), and death.</p><p><strong>Results: </strong>Among 8,800,359 hospitalizations (2.14% among patients with RA), 73.36% underwent intermediate-risk surgery and 62.25% had HFRS above 0. DHRN occurred in 28.9%, CACE occurred in 0.93%, and all-cause mortality occurred in 0.17%. A 10-point increase in HFRS was associated with a 3.8-fold increased DHRN, 8.5-fold increased CACE, and 22.8-fold increased mortality. RA was not independently associated with CACE (adjusted odds ratio [aOR] 0.91; 95% confidence interval [CI] 0.82-1.01; P = 0.08) or death (aOR 0.90; 95% CI 0.71-1.15; P = 0.41) but was significantly associated with DHRN (aOR 1.28, 95% CI 1.25-1.31; P < 0.001) after adjusting for confounders and frailty. In sensitivity analysis, RA had 10% higher relative odds of DHRN following orthopedic (aOR 1.10; 95% CI 1.07-1.13; P < 0.001) but not nonorthopedic intermediate-risk surgery (aOR 1.10; 95% CI 0.98-1.23; P = 0.11).</p><p><strong>Conclusion: </strong>RA was associated with higher odds of DHRN after orthopedic intermediate-risk surgery but not CACE or inpatient mortality. Moreover, HFRS was associated with DHRN, CACE, and death. These findings underscore the need for disease-specific clinical considerations and highlight the potential utility of HFRS in discharge planning.</p>","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":" ","pages":""},"PeriodicalIF":4.1,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149073411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Effectiveness of Tocilizumab and Tumor Necrosis Factor Inhibitors in Takayasu Arteritis: Age-Related Differences in Treatment Response.","authors":"Sreenidhi Sankararaman, Alessandro Tomelleri, Corrado Campochiaro, Luciana Yamamoto de Almeida, Chiara Bellino, Elena Baldissera, Lorenzo Dagna, Leonardo Salhani, Julia Shek, Peter C Grayson, Kaitlin A Quinn","doi":"10.1002/acr.80169","DOIUrl":"10.1002/acr.80169","url":null,"abstract":"<p><strong>Objective: </strong>Comparative, prospective data on biologics for Takayasu arteritis (TAK) are limited. We compared tumor necrosis factor inhibitors (TNFi) and tocilizumab (TCZ) in a combined cohort, assessed demographic and cytokine influences, and evaluated longitudinal outcomes.</p><p><strong>Methods: </strong>Clinical response to TNFi or TCZ was assessed in patients with TAK from two independent cohorts. In a subset followed prospectively within a standardized research protocol, physician global assessment (PGA), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) activity were compared pretreatment and posttreatment. Time to response was analyzed using Kaplan-Meier curves. Cytokine levels were measured with Luminex assays in patients and age-matched healthy controls.</p><p><strong>Results: </strong>Among 151 patients (cohort A = 57; cohort B = 94), 129 received TNFi and 56 received TCZ during follow-up. Clinical response rates were 72.1% for TNFi and 60.7% for TCZ (P = 0.17). In the prospective subset, no significant differences in PGA, CRP, ESR, or FDG-PET outcomes (P > 0.30) were observed. Changing to another TNFi or switching between TNFi or TCZ after treatment failure resulted in clinical response in 31 of 33 (94%) patients. TNFi responders had a younger median age at onset than nonresponders (23 vs 33.5 years, P = 0.0039), whereas TCZ responders were older (35 vs 21.5 years, P = 0.0043). Patients with onset <30 years showed elevated interleukin-6 and TNF versus controls, a pattern not observed in older patients.</p><p><strong>Conclusion: </strong>TNFi and TCZ demonstrated similar effectiveness in TAK. These findings support therapeutic switching after treatment failure and suggest that age-related immunologic differences may influence treatment response.</p>","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":" ","pages":""},"PeriodicalIF":4.1,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149068793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Safety of Concomitant Colchicine and Statin Therapy.","authors":"Roni Meidan, Ranel Loutati, Dan Caspi, Ori Elkayam, Ran Abuhasira, Tali Eviatar","doi":"10.1002/acr.80172","DOIUrl":"10.1002/acr.80172","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to evaluate the risk of clinically meaningful muscle- and liver-related outcomes associated with concomitant colchicine-statin therapy in a real-world setting, and to determine whether concomitant therapy increases the incidence of toxicity compared with either agent alone.</p><p><strong>Methods: </strong>This was a retrospective cohort study using the national Clalit Health Services database (≈5.4 million insured individuals). Adults with gout or familial Mediterranean fever between 2010 and 2024 were categorized into four exposure groups: no treatment, colchicine only, statin only, or concomitant therapy. Propensity-score matching was used to balance baseline characteristics. The primary outcome was creatine kinase (CK) elevation >3× the upper limit of normal (ULN), and secondary outcomes included alanine transaminase elevation >5× the ULN, myopathy, liver disease, and hospitalizations related to these conditions.</p><p><strong>Results: </strong>Eligible participants before and after propensity-score matching were 104,066 and 31,839, respectively (no treatment n = 7,146; colchicine only n = 7,146; statin only n = 9,030; concomitant therapy n = 8,517). Compared with no treatment, CK elevations >3× ULN were observed with statin therapy (hazard ratio [HR] 1.64 [95% confidence interval (CI) 1.39-1.93]) and concomitant colchicine-statin therapy (HR 1.74 [95% CI 1.44-2.09]) but not with colchicine therapy alone (HR 1.08 [95% CI 0.89-1.31]). Clinically diagnosed myopathy was infrequent and showed a graded increase across exposure groups, with the highest risk observed in the concomitant treatment group (HR 1.50 [95% CI 1.31-1.72]).</p><p><strong>Conclusion: </strong>Although colchicine-statin concomitant therapy was associated with higher rates of laboratory and clinical adverse events, the additional risk beyond statin monotherapy was small, supporting their use when clinically indicated.</p>","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":" ","pages":""},"PeriodicalIF":4.1,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149068840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment Sequencing and Line of Therapy for Biologics and JAK Inhibitors in Patients With Rheumatoid Arthritis: Implications for Design and Uptake of New Drugs and Predictive Biomarker Diagnostics","authors":"Jeffrey R. Curtis MD, MS, MPH,&nbsp;Shanette Daigle MPH,&nbsp;Emily E. Holladay MPH,&nbsp;Yujie Su MS,&nbsp;Michael George MD, MSCE,&nbsp;Gordon Lam MD,&nbsp;Robert Levin MD,&nbsp;Priya Reddy MD,&nbsp;Fenglong Xie PhD,&nbsp;Amy S. Mudano MPH","doi":"10.1002/acr.80025","DOIUrl":"10.1002/acr.80025","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>The opportunity for new biomarker-based tests to predict treatment response and the appropriate use of emerging rheumatoid arthritis (RA) therapies may depend on patients’ treatment history. We examined RA treatment sequences and biologic/JAK inhibitor (JAKi) initiation overall and by line of therapy (LoT) to estimate the size of the eligible RA patient population in the United States for a new predictive treatment response test using a population-based RA inception cohort.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We used an augmented health plan claims database to create an inception cohort of patients with RA and estimated the rate of advanced treatment (biologic or JAKi) addition or switch. Results were stratified by advanced treatment–naïve versus treatment-experienced status and also described specific RA treatment sequences and combinations over time.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among 37,656 patients with RA, 59,557 new RA treatment initiations were identified. Most patients (85.2%) initiated biologics; the remainder initiated JAKi. Of these, 40.2% used biologics/JAKi as monotherapy. The overall biologic/JAKi addition/switch rate was 25.7 per 100 patient-years (py) (22.7/100 py in biologic-naïve patients and &gt;30/100 py in treatment-experienced patients). Rates varied substantially between prescribers, with an observed add/switch rate in the practices of prescribers in the highest decile (53.8/100 py) more than four-fold greater than rates in the practice of prescribers in the lowest decile (12.1/100 py).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>These findings highlight the size and characteristics of the eligible RA population in the United States initiating a new RA biologic or JAKi treatment each year, thus providing valuable insights for stakeholders developing or marketing new RA therapies or biomarker-based diagnostic tests to predict future treatment response.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":"78 10","pages":"1387-1396"},"PeriodicalIF":4.1,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146199940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Lupus Damage Index Revision Program: Results From the Item Generation and Reduction Phases","authors":"Burak Kundakci MSc, PhD,&nbsp;Megan R. W. Barber MD, PhD,&nbsp;Ann E. Clarke MD, MSc, FRCPC,&nbsp;Sindhu R. Johnson MD, PhD,&nbsp;Anselm Mak MBBS, PhD, MD, FRCP, FRCPI,&nbsp;Hermine I. Brunner MD, MSc, MBA,&nbsp;Murat Inanc MD,&nbsp;Rosalind Ramsey-Goldman MD, DrPH,&nbsp;Guillermo Ruiz-Irastorza MD, PhD,&nbsp;Ellen M. Ginzler MD, MPH,&nbsp;John G. Hanly MD,&nbsp;Alexandra Legge MD, MSc,&nbsp;Cynthia Aranow MD,&nbsp;Laurent Arnaud MD, PhD,&nbsp;Nathalie Costedoat-Chalumeau MD, PhD,&nbsp;Dafna D. Gladman MD, FRCPC, OC,&nbsp;Søren Jacobsen MD, DMSc,&nbsp;Michelle Petri MD, MPH,&nbsp;Clovis A. Silva MD, PhD,&nbsp;Évelyne Vinet MD, PhD,&nbsp;Alexandre E. Voskuyl MD, PhD,&nbsp;SDI Revision Literature Review Groups,&nbsp;SDI Revision Delphi Panel,&nbsp;SDI Revision Item Reduction Committee,&nbsp;SDI Revision Clinical Domain Groups,&nbsp;Ian N. Bruce MD, FRCP","doi":"10.1002/acr.80102","DOIUrl":"10.1002/acr.80102","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>A data-driven and expert/patient consensus-based project to develop a revised Systemic Lupus International Collaborating Clinics (SLICC)/American College of Rheumatology (ACR) Damage Index (SDI) is under way supported by SLICC, ACR, and the Lupus Foundation of America. Our objective is to report the item generation and reduction phase results for a revised SDI.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Item generation included a literature review by literature review groups and a Delphi exercise of international systemic lupus erythematosus experts and patients. Item reduction involved Delphi rounds in which items with a median appropriateness score of ≤4 of 9 were excluded. A 14-member item reduction committee assessed remaining items and removed those that did not reflect the damage construct, were rare, or were not feasible to assess. The clinical domain groups then refined the remaining items and their definitions.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The Delphi panel included 146 individuals from 35 countries. The Delphi exercise nominated 2,256 items, and the literature review identified 117 items. After removing redundancies, 226 candidate items remained. Subsequent Delphi rounds, followed by review by the item reduction committee and clinical domain groups, resulted in 39 items across 13 domains. Eleven items from the original SDI, including proteinuria and cranial neuropathy, were removed and several new items were proposed, including growth failure/reduced final height and adrenal insufficiency. Severity-based subitems are proposed for 17 items (43.6%).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This data-driven and expert/patient consensus-based process has proposed 39 candidate items, some with subitems, and definitions for a revised SDI. Weighting of items and subitems is underway to develop a clinical scoring system.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":"78 10","pages":"1449-1466"},"PeriodicalIF":4.1,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/acr.80102","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148711174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Facilitating Expedited Drug Approval—the Past, Present, and Future of Clinical Trials for Pediatric Rheumatic Disease","authors":"Pamela F. Weiss MD, MSCE,&nbsp;Hermine I. Brunner MD, MSc, MBA","doi":"10.1002/acr.80028","DOIUrl":"10.1002/acr.80028","url":null,"abstract":"<p>All authors contributed to at least one of the following manuscript preparation roles: conceptualization AND/OR methodology, software, investigation, formal analysis, data curation, visualization, and validation AND drafting or reviewing/editing the final draft. As corresponding author, Dr Weiss confirms that all authors have provided the final approval of the version to be published and takes responsibility for the affirmations regarding article submission (eg, not under consideration by another journal), the integrity of the data presented, and the statements regarding compliance with institutional review board/Declaration of Helsinki requirements.</p>","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":"78 10","pages":"1317-1323"},"PeriodicalIF":4.1,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/acr.80028","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147281992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}